227 related articles for article (PubMed ID: 28448627)
1. Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies.
Li D; Bentley C; Yates J; Salimi M; Greig J; Wiblin S; Hassanali T; Banham AH
PLoS One; 2017; 12(4):e0176642. PubMed ID: 28448627
[TBL] [Abstract][Full Text] [Related]
2. MHC-Peptide Tetramers to Visualize Antigen-Specific T Cells.
Altman JD; Davis MM
Curr Protoc Immunol; 2016 Nov; 115():17.3.1-17.3.44. PubMed ID: 27801510
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201.
Trenevska I; Anderson AP; Bentley C; Hassanali T; Wiblin S; Maguire S; Pezzella F; Banham AH; Li D
PLoS One; 2021; 16(4):e0249967. PubMed ID: 33836029
[TBL] [Abstract][Full Text] [Related]
4. Construction of bioactive chimeric MHC class I tetramer by expression and purification of human-murine chimeric MHC heavy chain and beta(2)m as a fusion protein in Escherichia coli.
Ren D; Wang F; He X; Jiang L; Li D; Ying H; Sun S
Protein Expr Purif; 2006 Dec; 50(2):171-8. PubMed ID: 17046278
[TBL] [Abstract][Full Text] [Related]
5. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
6. An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/peptide complexes.
Kawana-Tachikawa A; Tomizawa M; Nunoya J; Shioda T; Kato A; Nakayama EE; Nakamura T; Nagai Y; Iwamoto A
J Virol; 2002 Dec; 76(23):11982-8. PubMed ID: 12414940
[TBL] [Abstract][Full Text] [Related]
7. T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy.
Duan Z; Ho M
Mol Cancer Ther; 2021 Sep; 20(9):1533-1541. PubMed ID: 34172530
[TBL] [Abstract][Full Text] [Related]
8. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
9. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Antibodies against Intracellular Tumor Antigens.
Trenevska I; Li D; Banham AH
Front Immunol; 2017; 8():1001. PubMed ID: 28868054
[TBL] [Abstract][Full Text] [Related]
11. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.
Verma B; Hawkins OE; Neethling FA; Caseltine SL; Largo SR; Hildebrand WH; Weidanz JA
Cancer Immunol Immunother; 2010 Apr; 59(4):563-73. PubMed ID: 19779714
[TBL] [Abstract][Full Text] [Related]
12. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.
Inaguma Y; Akahori Y; Murayama Y; Shiraishi K; Tsuzuki-Iba S; Endoh A; Tsujikawa J; Demachi-Okamura A; Hiramatsu K; Saji H; Yamamoto Y; Yamamoto N; Nishimura Y; Takahashi T; Kuzushima K; Emi N; Akatsuka Y
Gene Ther; 2014 Jun; 21(6):575-84. PubMed ID: 24694533
[TBL] [Abstract][Full Text] [Related]
13. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
[TBL] [Abstract][Full Text] [Related]
14. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
[TBL] [Abstract][Full Text] [Related]
15. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
Denkberg G; Reiter Y
Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
[TBL] [Abstract][Full Text] [Related]
16. Chimeric beta2 microglobulin/CD3zeta polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: a potential tool for specific targeting of pathogenic CD8(+) T cells.
Margalit A; Fishman S; Berko D; Engberg J; Gross G
Int Immunol; 2003 Nov; 15(11):1379-87. PubMed ID: 14565936
[TBL] [Abstract][Full Text] [Related]
17. Porcine major histocompatibility complex (MHC) class I molecules and analysis of their peptide-binding specificities.
Pedersen LE; Harndahl M; Rasmussen M; Lamberth K; Golde WT; Lund O; Nielsen M; Buus S
Immunogenetics; 2011 Dec; 63(12):821-34. PubMed ID: 21739336
[TBL] [Abstract][Full Text] [Related]
18. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
[TBL] [Abstract][Full Text] [Related]
19. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
[TBL] [Abstract][Full Text] [Related]
20. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
Lustgarten J; Waks T; Eshhar Z
Eur J Immunol; 1991 Oct; 21(10):2507-15. PubMed ID: 1915555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
